

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
24 February 2005 (24.02.2005)

PCT

(10) International Publication Number
WO 2005/015990 A1

- (51) International Patent Classification⁷: **A01K 67/027**
- (21) International Application Number:
PCT/SE2004/001209
- (22) International Filing Date: 18 August 2004 (18.08.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/481,249 18 August 2003 (18.08.2003) US
60/481,608 7 November 2003 (07.11.2003) US
60/521,377 14 April 2004 (14.04.2004) US
- (71) Applicants (for all designated States except US): **BETAGENON AB** [SE/SE]; P O Box 2339, S-103 18 STOCKHOLM (SE). **YEDA RESEARCH AND DEVELOPMENT CO LTD** [IL/IL]; P O Box 95, 76100 REHOVOT (IL).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **EDLUND, Helena** [SE/SE]; Mellanbågen 18, S-907 38 UMEÅ (SE). **WALKER, Michael D.** [IL/IL]; 40 Sderot Hen, Apartment 12, 76469 REHOVOT (IL). **RUBINS, Nir** [IL/IL]; 2 Neve Alon Street, Apartment 29, 76455 REHOVOT (IL). **STENEBERG, Pär** [SE/SE]; Kustvägen 73, S-905 80 UMEÅ (SE).
- (74) Agent: **ALBIHNS STOCKHOLM AB**; P.O. Box 5581, S-114 85 Stockholm (SE).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NEW DIABETES TYPE 2 ANIMAL MODEL

(57) Abstract: A diabetes type 2 model laboratory animal is disclosed which comprises cells over-expressing GRP40 under the control of the Ipfl/Pdx1 promoter. Also disclosed is the use of the model animal for the identification of agonists or antagonists towards GRP40, useful for the development of pharmaceuticals towards treatment of the disease.



WO 2005/015990 A1

Title: New diabetes type 2 animal model.

Technical field

5 The present invention relates to an animal model, in particular a transgenic mouse over-expressing GPR40 under the control of the *Ip1f1/Pdx1* promoter for identification of ligands that interacts with GPR40. The mouse could be used for screening therapeutic agents influencing the GPR40 receptor and its pathways. The present invention also relates to assay systems and methods
10 for screening of therapeutic agents. Examples of diseases involving interaction of GPR40 are diabetes, obesity, cancer (Yonezawa et al (Biochem. Biophys. Res. Commun.2004, (314) 805-809, neurodegenerative disease (for example Alzheimer's disease, Parkinson's and Huntington's diseases) and other indications such as stroke.

15 Diabetes is just one of the diseases that could be treated with drugs that interfere with the GPR40 receptor and the background for Type 2 diabetes should therefore only be seen as an example to the invention.

20 **Technical background**

Type 2 diabetes mellitus is a contemporary global epidemic with over 150 million people currently affected, and with an expected increase of 5-6 million cases per year. Obesity, western dietary habits, lack of physical activity and
25 aging will continue to drive dramatic growth of type 2 diabetes for decades to come. Type 2 diabetics exhibit reduced action of insulin in skeletal muscle, fat and liver cells combined with reduced insulin secretion from the pancreatic β -cells. Type 2 diabetes develops after β -cell defects arise. Thus, by improving the adaptive β -cell response, diabetes may be treated properly. In order to find
30 new novel treatment for Type 2 diabetes there is a need for new animal

models of diabetes, namely models in which the pancreatic β -cells are defective, leading to one or more conditions or symptoms that are characteristic of diabetes. Such a model could be serving in screenings assays for the identification of agents that partially or totally compensate for the β -cell defect. Glucose is an effective and fast stimulator of insulin secretion from storage granules in β -cells. The low-affinity glucose transporter type 2, (Glut2), ensures an efficient glucose uptake by the β -cell and in the cell glucose becomes phosphorylated by the key glycolytic enzyme glucokinase. Oxidative metabolism of glucose then subsequently leads to an increase in the cytosolic ATP/ADP ratio, which in turn results in a closure of the ATP-sensitive K^+ ATP transmembrane channel. The resulting membrane depolarisation and subsequent activation of the voltage gated Ca^{2+} -channel then leads to an influx of Ca^{2+} that stimulates exocytic release of insulin and C-peptide into the bloodstream (for review see Easom et al 2000). Thus, efficient glucose uptake and subsequent metabolism ensures the generation of the secondary signals that are critical for glucose stimulated insulin secretion (GSIS). Other nutrients such as amino acids and free fatty acids (FFA) as well as hormones also influence insulin secretion but these molecules rather appear to potentiate the stimulatory effect of glucose rather than directly stimulate insulin secretion from β -cells (Rutter 2001; Zraika et al. 2002). Although fatty acids increase GSIS prolonged exposure to high concentrations of fatty acids impairs GSIS (Patane, 2003, Jean E. Schaffer. Curr Opin Lipidol 2003). The mechanisms behind the positive and negative effects of fatty acids on GSIS remain, however, largely unknown.

Type 2 Diabetics respond inadequately to a glucose challenge, i.e. glucose intolerance diabetics and often show early signs of impaired GSIS, and loss of first-phase insulin secretion. In most cases this β -cell dysfunction progresses further, leading to complete β -cell failure and manifestation of overt diabetes in the affected individuals. The diabetic state of the individual, i.e. hyperglycemia and hyperlipidemia, are thought to contribute to the deterioration of β -cell

function but the molecular mechanisms involved have remained also largely unknown (Zraika et al. 2002; Kashyap et al. 2003).

The recently identified G-protein coupled receptor GPR40 is expressed in adult β -cells (Briscoe et al 2003, Itoh et al 2003, Kotarsky et al 2003, WO-A2-02/057783). GPR40 belongs to a novel class of G-protein coupled receptors that also includes GPR41 and GPR43 (Briscoe, Itoh, Kotarsky and Brown et al 2003) and activation of GPR40 in cell lines result in an increase in intracellular Ca^{2+} concentration and induces MAPK activity (Itoh 2003).

Moreover, long-chain fatty acids enhance GSIS from insulinoma cell lines in a GPR40 dependent manner (Itoh 2003). Hence, GPR40 provides a potential candidate link between FFAs and GSIS. Lipotoxicity, i.e. perturbed β -cell function and severely impaired GSIS due to elevated levels of FFAs, becomes manifest first after long-term exposure to FFA, suggesting that over-stimulation rather than loss of function of a FFA responsive receptor with time may lead to deterioration of β -cell function, impaired GSIS, and the development of diabetes. Thus, both agonist and antagonist of GPR40 activity could be of therapeutic value for diabetes, and in particular Type 2 diabetes. Antagonist will be used for prevention of diabetes in individual with elevated levels of FFA and reduction of lipotoxicity and thus improve the function of the β -cells, and agonist for treatment of diabetes in order to stimulate GSIS. Antagonists could also be used to inhibit the proliferation of cancer cells.

Summary of the invention

It is an object of the present invention to provide assay methods for screening of therapeutic agents that interact with the GPR40 receptor and could be used for development of novel drugs.

It is an object of the present invention to provide an animal model for screening of therapeutic agents that interact with the GPR40 receptor. The animal may be a rodent e.g. a rat or a mouse and preferably a mouse, but

other laboratory animals such as monkeys, rabbits and guinea-pigs may be used.

It is an object of the present invention to provide a method for identifying agents that increase impaired insulin secretion in pancreatic β -cells by acting as a GPR40 agonist or agents acting as antagonist which will be used for prevention of diabetes in individual with elevated levels of FFA. The test agent is determined to be active as an antagonist if it increases Glut2 expression in the exposed transgenic mice, or lower the blood glucose levels, restores glucose tolerance and proinsulin processing.

It is an object of the present invention to describe compounds that antagonize the GPR40 receptor and therefore could be used to inhibit cellular proliferation for the development of cancer treatments.

It is an object of the present invention to provide an animal model which mimic human Type 2 diabetes and which can be used to develop a therapy.

Further objects of the invention will become evident from the study of the following short description of the invention and preferred embodiments thereof, the figures illustrating the invention, and the appended claims.

Detailed description of invention

In a first aspect, the present invention provides a transgenic laboratory animal over-expressing GPR40 comprising the promotor *lpl1/Pdx1* for controlling the expression of GPR40. The transgenic animal is preferably a rodent such as a mouse or a rat, but could be another useful laboratory animal.

In a second aspect, the present invention provides a method for testing whether a chemical compound possessing a certain effect for treating diabetes Type 2 using a transgenic laboratory animal comprising the steps of:

a) providing a chemical compound to be tested;

5 b) providing a transgenic laboratory animal according to claim 1;

c) exposing said animal to said chemical compound; and

d) determining whether said chemical compound has an effect on the blood glucose level, triglyceride level, low density lipoprotein (LDL), high density lipoprotein (HDL), free fatty acids and/or glucose tolerance in said animal.

10

Definitions

The term "chemical compound" refers to any chemical entity, pharmaceutical, drug, and the like that is suspected to affect diabetes Type 2 or cancer.

15 Possible chemical compounds comprise both known and potential therapeutic compounds. A chemical compound can be determined to affect diabetes type 2 or cancer by exposing a transgenic animal according to the present invention to said chemical compound for a suitable amount of time, followed by monitoring known diabetes type 2 or cancer associated characteristics, such as blood glucose level, triglyceride level, low density lipoprotein (LDL), high density lipoprotein (HDL), free fatty acids and/or glucose tolerance.

25 A chemical compound is said to be "in a form suitable for administration such that the chemical compound is bio-available in the blood of the animal" when the chemical compound may be administered to an animal by any desired route (e.g., oral, intravenous, subcutaneous, intrathecal, intraperitoneal, intramuscular, etc.) and the chemical compound or its active metabolites appears in the blood of the animal in an active form.

30 Following initial screening, a chemical compound that appears promising is further evaluated by administering various concentrations of the chemical

compound to the transgenic animals provided herein in order to determine an approximate therapeutic dosing range.

Animal testing may be supplemented and confirmed by testing on human subjects. However, the animal models herein provided allow the testing of a large number of compounds, both by the methods described above and other methods known in the art, in a system similar in many important respects to that in humans.

As used herein, "agent" refers to a compound, complex or substance, natural or man-made.

As used herein, "GPR40" refers to a receptor which is disclosed in for example references (Briscoe et al 2003, Itoh et al 2003, Kotarsky et al 2003, WO-A2-02/057783). GPR40 refers to a receptor polypeptide having at least 95% identity to the polypeptide sequence given in SEQ ID No: 1 and having GPR40 function. An example of the GPR40 receptor is provided in the polypeptide sequence of SEQ ID No: 1. An example of a nucleic acid sequence encoding GPR40 is disclosed as SEQ ID No:2.

As used herein, "Ip1/Pdx1" is a promotor sequence which is disclosed in reference (Apelqvist 1997).

Summary

Over-expression of GPR40 behind the Ip1/Pdx1 promoter in mice leads to diabetes. The diabetic phenotype may in part result from loss of Glut2 expression in β -cells of the Ip1/GPR40 mice. These data suggest that levels of GPR40 and/or activity need to be carefully controlled to assure normal β -cell function. Hence, these mice represent an important animal model that can be

used to identify substances capable of modulating GPR40 activity and/or expression and thus blood glucose levels.

Test agents are screened from large libraries of synthetic or natural
5 compounds. Numerous means are currently used for random and directed
synthesis of saccharide, peptide, nucleic acid and heterocyclic based
compounds. Examples of active compounds include also known GPCR
binding scaffolds known for the person skilled in the art. Synthetic compound
libraries are commercially available from companies such as Chembridge
10 (Russia), Maybridge Chemical Co. (UK) Chemical Diversity (Russia),
Comgenex (Hungary), Asinex (Russia) etc. Libraries of natural compounds in
the form of bacterial, fungal, plant and animal extracts are available from e.g.
Pan Laboratories(USA), MycoSearch (USA) or are readily producible.
The agent could also be in the form of pharmaceutically acceptable salt,
15 prodrugs.

Examples of pharmaceutically acceptable addition salts for use in the
pharmaceutical compositions of the present invention include those derived
from mineral acids, such as hydrochlorid, hydrobromic, phosphoric,
20 metaphosphoric, nitric and sulphuric acids, and organic acids, such as tartaric,
acetic, citric, malic, lactic, fumaric, benzoic, glycolic, gluconic, succinic, and
arylsulphonic acids. The pharmaceutically acceptable excipients described
herein, for example, vehicles, adjuvants, carriers or diluents, are well-known to
those who are skilled in the art and are readily available to the public. The
25 pharmaceutically acceptable carrier may be one which is chemically inert to
the active compounds and which have no detrimental side effects or toxicity
under the conditions of use. Pharmaceutical formulations are found e.g. in
Remington: The Science and Practice of Pharmacy, 19th ed., Mack Printing
Company, Easton, Pennsylvania (1995).

Examples of prodrugs include, but are not limited to, esters and carbamates of hydroxy functional groups, esters groups of carboxyl functional groups, N-acyl derivatives, N-Mannich bases. General information on prodrugs may be found e.g. in Bundegaard, H. "Design of Prodrugs" pl-92, Elsevier, New York-

Oxford (1985).

The agents according to the invention may be prepared for any route of administration, e.g. oral, intravenous, cutaneous or subcutaneous, nasal, intramuscular, or intraperitoneal. The precise nature of the carrier or other material will depend on the route of administration. For a parenteral administration, a parenterally acceptable aqueous solution is employed, which is pyrogen free and has requisite pH, isotonicity, and stability. Those skilled in the art are well able to prepare suitable solutions and numerous methods are described in the literature. A brief review of methods of drug delivery is also found in e.g. Langer, Science 249:1527-1533 (1990).

The dose administered to a mammal, particularly a human, in the context of the present invention should be sufficient to effect a therapeutic response in the mammal over a reasonable time frame. One skilled in the art will recognize that dosage will depend upon a variety of factors including the potency of the specific compound, the age, condition and body weight of the patient, as well as the stage/severity of the disease. The dose will also be determined by the route (administration form) timing and frequency of administration. In the case of oral administration the dosage can vary from about 0.01 mg to about 1000 mg per day or the corresponding amount of a pharmaceutically acceptable salt thereof.

Brief description of the drawings

Figure 1 shows perturbed Islet morphology in *IPF-1/GPR40* mice and wild type mice.

Figure 2a shows Insulin and Glucagon double-staining in wild type mice.

Figure 2b shows Insulin and Glucagon double-staining in *IPF-1/GPR40* mice. **Figure 3a** shows Insulin and Somatostatin double staining in wild type mice. **Figure 3b** shows Insulin and Somatostatin double staining in *IPF-1/GPR40* mice.

5 **Figure 4a** shows Isl1 and PP double staining in wild type mice.

Figure 4b shows Isl1 and PP double staining in *IPF-1/GPR40* mice.

Figure 5a,c,e,g shows the expression of factors involved in glucose sensing and proinsulin processing is perturbed in wild type mice.

10 **Figure 5b,d,f,h** shows the expression of factors involved in glucose sensing and proinsulin processing is perturbed in *lpf1/GPR40* mice.

Figure 6a shows insulin radio immune assay (RIA) of total pancreatic protein extracts in wild type and *lpf1/GPR40* mice.

Figure 6b shows quantitative real time PCR of insulin mRNA from isolated islet cDNA of wild type and *lpf1/GPR40* mice.

15 **Figure 7a** shows the glucose tolerance test of *lpf1/GPR40* and wild type mice.

Figure 7b shows the insulin secretion in response to glucose challenge of *lpf1/GPR40* and wild type mice.

20 **Figure 8a,b** shows impaired insulin secretion in *lpf1/GPR40* transgenic mice where the serum insulin levels were determined in wild type and *lpf1/GPR40* mice after intraperitoneal injection of glucose into over-night fasted animals.

Figure 9 shows a map on construct.

Several diseases could be treated by compounds which interact with the GPR40 receptor and in order to investigate the function of GPR40 in vivo the
25 inventors have generated transgenic mice carrying over-expressing GPR40 β -cells under the control of the *lpf1/Pdx1* promoter (Apelqvist 1997), see Figure 1. This animal model could be used for studies of Type 2 diabetes. Other animal models could be developed in the same approach for the studies of other diseases. The resulting transgenic mice carrying over-expressing
30 GPR40 β -cells were born alive and appeared initially healthy but developed diabetes with age, see Table 1, suggesting that forced expression of *GPR40* in

adult β -cells perturb β -cell function. The results, as described below, from the transgenic mice point to new ways in which manipulation of the expression of the GPR40 lead to diabetes and could be used for studying novel therapeutic agents for the treatment of diabetes.

5

GPR40 transgene expression in early (e10) pancreatic progenitor cells (right panel).

Table 1

	Mean conc. of Blood glucose (mmol/l)			
	9 days	21 days	32 days	40 days
Wt	3,8 (1)	8,1 (9)	9,3 (9)	9,3 (8)
<i>lpf-1/GPR40</i>	7,2 (6)	11,9 (9)	19,3 (9)	16,4 (8)

- 10 Blood glucose levels are elevated in *lpf-1/GPR40* transgenic as compared to wild type littermates as shown in Table 1.

Pancreases

- Analyses of isolated pancreases 10 weeks old mice showed no apparent
 15 difference in overall organ size between transgenic and wild type littermates (not shown). Whole mount immunostaining of the pancreases derived from transgenic and wild-type mice using antibodies against Insulin, Glucagon and alpha-Smooth Muscle Actin revealed a normal organisation of major blood vessels and a normal distribution of clustered pancreatic endocrine cells, i.e.
 20 islets, in the transgenic mice, see Figure 1. Nevertheless, the intercellular organization of endocrine cells in the islets appeared perturbed and the islets of the transgenic mice lack the normal organization of glucagon expressing α -cells surrounding a core of tightly clustered β -cells and instead the glucagon expressing α -cells appear interspersed within the islets of *lpf-1/GPR40* mice.
 25 Hence, the more purple colour of islets in transgenic mice, see Figure 1, right panel. Perturbed Islet morphology in *IPF-1/GPR40* mice.

Immunostaining of sectioned pancreas derived from wild type and transgenic mice using antibodies directed against insulin, glucagons, somatostatin, Isl1 and pancreatic polypeptide (PP) confirmed the abnormal organisation of the endocrine cells within the islets of transgenic mice, see Figure 2b, 3b and 4b. Figure 2a,b shows insulin and Glucagon double-staining. Figure 3a,b shows insulin and Somatostatin double staining and Figure 4a,b shows Isl1 and PP double staining.

10 **Molecular defects**

To begin to identify the molecular defects underlying the development of diabetes in the *lpf1/GPR40* mice analysis of the expression of factors known to be critically required for β -cell function where performed.

15 **Glut 2 and PC1/3**

Long-term exposure of islets to elevated FFA in vitro results in an impaired expression of factors controlling β -cell function (Gremlich et al 1997, Zhou et al 2003). One such factor is Glut2, the expression of which is also perturbed in a variety of diabetic animal models (Efrat 2003). In the *lpf1/GPR40* mice the expression of Glut2 was virtually undetectable providing evidence that Glut2 expression is down-regulated in *lpf1/GPR40* mice, see Figure 5a,b.

Another factor is the prohormone convertase 1/3 (PC1/3), one of the key enzymes involved in proinsulin to insulin processing, The expression of PC1/3 was reduced in the *lpf1/GPR40* mice, see Figure 5c,d which give an increased proinsulin-to-insulin (P/I) ratio. The increase ratio is associated with type 2 diabetes. The proinsulin immunoreactivity was readily detectable in β -cells of the *lpf1/GPR40* mice see, Figure 5e,f. The reduced expression of Glut2 and PC1/3 will lead to perturbed glucose sensing and proinsulin processing in β -cells of *lpf1/GPR40* mice and are likely to contribute to the impaired GSIS and development of diabetes observed in these mice. This was confirmed by

immunohistochemical analyses using anti-proinsulin specific antibodies that revealed an increased amount of proinsulin in β -cells of *lpf1/GPR40* mice as compared to wild type mice, see Figure 5e,f. These data suggest that *GPR40* expression and/or activity in adult β -cells need to be tightly balanced to ensure normal GSIS and hence glucose homeostasis.

Figure 5 shows the expression of factors involved in glucose sensing and proinsulin processing is perturbed in *lpf1/GPR40* mice. a-d, Analyses of Glut2 (a,b) and PC1/3 (c,d) expression show that Glut2 expression is impaired and PC1/3 expression reduced in β -cells of *lpf1/GPR40* mice. e-g, Proinsulin processing is perturbed in *lpf1/GPR40* mice and hence in addition to insulin (g,h), proinsulin (e,f) immunoreactivity is readily observed in β -cells of the *lpf1/GPR40* mice.

Proinsulin and insulin

Hypersecretion of insulin and proinsulin followed by hypoinsulinaemia is associated with the progression of type 2 diabetes as mentioned above and long-term exposure of islets to elevated levels of FFAs also leads to increased secretion, predominantly of proinsulin, and depletion of insulin content (Furukawa et al., Diabetes 48, 1395-1401, 1999; Bjorklund & Grill, Diabetes, 48,1409-1414, 1999). The total pancreatic insulin content was severely reduced in the *lpf1/GPR40* mice, see Figure 6a, suggesting perturbed insulin gene expression and or/insulin storage in *lpf1/GPR40* mice. The impaired GSIS observed in the *lpf1/GPR40* mice may hence, at least in part, result from a shortage of ready releasable insulin. Real-time PCR analyses of insulin mRNA levels revealed that insulin gene expression was normal in *lpf1/GPR40* mice, see Figure 6b. Taken together these data show that pancreatic development, β -cell generation, and insulin gene expression is normal but that pancreatic insulin content is reduced in *lpf1/GPR40* mice, resembling the condition observed in type 2 diabetics and islets exposed elevated FFAs.

Reduced pancreatic insulin content but normal insulin gene expression in lpf1/GPr40 mice, see Figure 6a and 6b. Figure 6a shows insulin radio immune assay (RIA) of total pancreatic protein extracts, showing that the total pancreatic insulin content is reduced by ~78% in lpf1/GPR40 mice (blue) as compared to wild type controls (pink). Figure 6b shows, quantitative real time PCR of insulin mRNA from isolated islet cDNA of wild type (blue, n=3) and lpf1/GPR40 (pink, n=3) mice showing that insulin gene expression is normal in the lpf1/GPR40 mice.

Glucose tolerance test

Glucose tolerance test (Ulf Ahlgren et. Al. 1998) and determination of GSIS by measuring serum insulin levels in response to exogenous glucose to overnight fasted mice revealed a severely impaired glucose tolerance in these mice, a loss of first-phase insulin release and a delayed, blunted second phase insulin release in the lpf1/GPR40 mice as compared to the wild-type controls, see Figure 7a and Figure 7b.

Figure 7a shows that the lpf1/GPR40 mice are glucose intolerant. Glucose tolerance test of lpf1/GPR40 (♦, n=4) and wild type mice (■, n=2) showing blood glucose levels (shown as mmol/l on the x-axis) after intraperitoneal (i.p.) injection of glucose into over-night fasted mice. Average values. Figure 7b shows the impaired insulin secretion in lpf1/GPR40 transgenic mice. Serum insulin levels (shown as ng/ml on the x-axis) were determined in wild type (■, n=2) and lpf1/GPR40 (♦, n=4) mice after i.p. injection of glucose into over-night fasted animals. Average values.

Free fatty acids

A human cell surface receptor is activated by free fatty acids and thiazolidinedione drugs. Measurements of free fatty acids is disclosed in references (Knut Kotarsky 2003 and Jean E. Schaffer 2003).

Measurements of triglyceride level, low density lipoprotein (LDL) level and high density lipoprotein (HDL) level is known to the skilled person in the art. Some measurement methods are disclosed in US 4125377, US 4920123 and US 6764828.

5

UCP2, PPAR, Cpg21, MKP 3 and CREM-17X

A number of different factors, including the dual-specific MAPK-phosphatase Cpg21, cAMP response element modulator (CREM)–17X, the peroxisome proliferator-activated (PPAR) α , and its downstream target genes carnitine
10 palmitoyltransferase 1 (CPT1) and uncoupling protein 2 (UCP2,) are all up-regulated rather than down regulated in islets exposed to long-term FFAs (Zraika et al 2002, Zhou 2003). Real-time PCR analysis showed that the expression of PPAR α , UCP2, and the dual-specificity MAPK phosphatases (MKP) 3 were up-regulated in *lpl1/GPR40* mice, whereas the expression of
15 PPAR γ , a gene linked to type 2 diabetes, was reduced, see Figure 8a,b. The expression of CPT1 was up-regulated 6-fold in *lpl1/GPR40* mice. The virtually abolished expression of Glut2 was confirmed on the mRNA level, see Figure 8a,b. A number of genes, including the transcription factors *lpl1/Pdx1* and *Isl1*, the fibroblast growth factor receptor (*Fgfr*) 1, and glucokinase (GCK),
20 Cpg21, and CREM-17X, showed unchanged or moderately altered expression levels (Figure 8a,b and data not shown).

Figure 8a,b shows quantitative real time PCR on islet cDNA from wild type (pink, n=3) and *lpl1/GPR40* (blue, n=3) mice, demonstrating that Glut2
25 expression is virtually abolished, PPAR γ reduced, UCP2, MKP3 and PPAR α expression increased.

cp-2 is known to impair GSIS by uncoupling respiration from oxidative phosphorylation, which in turn leads to reduced ATP-production. The exact
30 role of PPARs in β -cell function is poorly understood but PPARs are fatty acid sensors that regulate genes involved in oxidation and lipogenesis. PPAR α

have been shown to stimulate UCP2 expression and impair insulin secretion in an insulinoma cell line (Tordjman et al 2002). Attenuation of FGFR1c signalling in mouse β -cells leads to diabetes, partly due to impaired expression of Glut2 and PC1/3 (Hart et al 2000), and FGF signalling is known to activate the
5 MEK/MAPK (Szebenyi et al 1999). Dual-specificity phosphatases, such as MKP3, are in turn known to dephosphorylate and inactivate ERK, leading to inhibition of MAPK-dependent FGF-signalling (Keyse, 2000). The up-regulation of MKP3 expression observed in the *lpf1/GPR40* mice would thus impair the FGFR1c signalling in β -cells. Together these data demonstrate that
10 forced expression of GPR40 in adult β -cells in vivo perturbs the expression of factors required for appropriate glucose sensing, oxidative metabolism, and proinsulin to insulin processing.

Generation of *lpf1/GPR40* transgenic mice

15 The *GPR40* coding ORF was isolated as a 930-basepair XbaI-BglII restriction fragment from clone E7 (Michael Walker). Following fill in of 5'-overhang the isolated fragment was cloned behind the *lpf1/Pdx1* promotor (Apelqvist, 1997). Transgenic mice were generated by pronuclear injection of a purified 6.5-kb NotI-BssHII restriction-fragment encompassing the *lpf1/Pdx1* promotor
20 followed by the *GPR40* cDNA into F2 hybrid oocytes from B6/CBA parents as described (Hogan B. *Manipulating the mouse embryo*, 1994). Genomic DNA extracted from tail biopsies or embryonic heads were used in PCR analyses to determine the genotype of transgenic animals. The primers used were: 5'-GGGAAGAGGAGATGTAGACTT-3' (*lpf1/Pdx1* primer for 5') and 5'-
25 GTAGAGGGGAGCAAAGTG-3' (*GPR40* primer 3'). Expression from the transgene was confirmed by in situ staining on e10 embryos.

The promotor Islet amyloid (IAPP) (Hull et. Al. 2004), could also be used to generate transgenic mice over-expressing GPR40 in beta cells.

Glucose and Insulin measurements

All functional analyses were performed in vivo using overnight fasted mice that were injected intraperitoneally with the Glucose (1g/kg) body weight. Blood samples were obtained from the tail vein before glucose injection (time 0 min) and at 2.5, 5, 10, 20, 40, 80 and 120 minutes after glucose injection. Blood glucose levels were measured using a Glucometer Elite (Bayer Inc.) and serum insulin levels were measured using ELISA (Mercodia) according to the manufacturers recommendations.

Quantification of mRNA expression levels

cDNA was prepared from total RNA prepared from isolated islets (Ahren, 1997) using NucleoSpin RNAII-kit (#635990, Machery-Nagel) and Super SMART PCR (#635000, Clontech). Real time PCR analysis was performed using the ABI PRISM 7000 Sequence Detection System and SYBR Green PCR Master Mix (ABI) according to the manufacturers recommendations.

In Situ hybridizations and immunohistochemistry

In Situ hybridisations using a DIG-labelled probe corresponding to mouse GPR40 cDNA was carried out as described (Apelqvist, 1997).

Immunohistochemical localization of antigens and double-label immunohistochemistry was carried out as described (Apelqvist, 1997). Primary antibodies used were: guinea pig-anti-Insulin (Linco), rabbit-anti-Glucagon (EuroDiagnostica), rabbit-anti-Glucose transporter 2 (kindly provided by B. Thorens, Lausanne, Switzerland), rabbit-anti-Prohormone convertase 1/3 (Chemicon), rat-anti-Somaostatin (Biogenesis), guinea pig-anti-Pancreatic polypeptide (Linco), rabbit-anti-Islet1 (kindly provided by T. Edlund, Umeå, Sweden). Secondary antibodies used were: ALEXA 488-anti-guinea pig (Molecular Probe), Cy3-anti-rabbit and Cy3-anti-rat (Jackson laboratory).

REFERENCES

- Ahren B, Simonsson E, Scheurink AJ, Mulder H, Myrsen U et al. Dissociated insulinotropic sensitivity to glucose and carbachol in high-fat diet-induced insulin resistance in C57BL/6J mice. *Metabolism* 46: 97-106 (1997).
- 5 Apelqvist A, Ahlgren U, Edlund H. Sonic hedgehog directs specialised mesoderm differentiation in the intestine and pancreas. *Curr Biol* 7:801-8044 (1997).
- Briscoe CP, Tadayyon M, Andrews JL, Benson WG, Chambers JK, Eilert MM, Ellis C, Elshourbagy NA, Goetz AS, Minnick DT, Murdock PR, Sauls HR Jr, Shabon U, Spinage LD, Strum JC, Szekeres PG, Tan KB, Way JM, Ignar DM, Wilson S, Muir AI. The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids. *J Biol Chem.* 278:11303-11311 (2003).
- 10 Brown AJ, Goldsworthy SM, Barnes AA, Eilert MM, Tcheang L, Daniels D, Muir AI, Wigglesworth MJ, Kinghorn I, Fraser NJ, Pike NB, Strum JC, Steplewski KM, Murdock PR, Holder JC, Marshall FH, Szekeres PG, Wilson S, Ignar DM, Foord SM, Wise A, Dowell SJ. The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. *J Biol Chem.* 278:11312-11319 (2003).
- 15 Bjorklund, A., & Grill, V. Enhancing effects of long-term elevated glucose and palmitate on stored and secreted proinsulin-to-insulin ratios in human pancreatic islets. *Diabetes*, 48:1409-14 (1999).
- Easom RA. Beta-granule transport and exocytosis. *Semin Cell Dev Biol* 11, 253-66 (2000).
- 25 Furukawa H, Carroll RJ, Swift HH, Steiner DF. Long-term elevation of free fatty acids leads to delayed processing of proinsulin and prohormone convertases 2 and 3 in the pancreatic beta-cell line MIN6. *Diabetes*, 48:1395-1401 (1999).
- Gremlich S, Bonny C, Waeber G, Thorens B. Fatty acids decrease IDX-1 expression in rat pancreatic islets and reduce GLUT2, glucokinase, insulin, and somatostatin levels. *J Biol Chem.*;272:30261-30269 (1997).
- 30

- Hart AW, Baeza N, Apelqvist A, Edlund H. Attenuation of FGF signalling in mouse beta-cells leads to diabetes. *Nature* 408(6814): 864-868. (2000).
- Hogan, B., Beddington, R., Costantini, F. & Lacy, E n. Manipulating the Mouse Embryo. *Cold Spring Harbour Laboratory Press*, 1994.
- 5 Itoh Y, Kawamata Y, Harada M, Kobayashi M, Fujii R, Fukusumi S, Ogi K, Hosoya M, Tanaka Y, Uejima H, Tanaka H, Maruyama M, Satoh R, Okubo S, Kizawa H, Komatsu H, Matsumura F, Noguchi Y, Shinohara T, Hinuma S, Fujisawa Y, Fujino M. Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. *Nature* 422:173-176 (2003).
- 10 Kashyap S, Belfort R, Gastaldelli A, Pratipanawatr T, Berria R, Pratipanawatr W, Bajaj M, Mandarino L, DeFronzo R, Cusi K. A sustained increase in plasma free Fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. *Diabetes* 52:2461-2474 (2003).
- 15 Keyse SM. Protein phosphatases and the regulation of mitogen-activated protein kinase signalling. *Curr Opin Cell Biol.* 12:186-192 (2000).
- Kotarsky K, Nilsson NE, Flodgren E, Owman C, Olde B. Kotarsky K, Nilsson NE, Flodgren E, Owman C, Olde B. A human cell surface receptor activated by free fatty acids and thiazolidinedione drugs. *Biochem Biophys Res Commun.* 301:406-410 (2003).
- 20 Patane G, Anello M, Piro S, Vigneri R, Purrello F, Rabuazzo AM. Role of ATP production and uncoupling protein-2 in the insulin secretory defect induced by chronic exposure to high glucose or free fatty acids and effects of peroxisome proliferator-activated receptor-gamma inhibition. *Diabetes* 51:2749-2756 (2002).
- 25 Rutter GA. Nutrient-secretion coupling in the pancreatic islet β -cell: recent advances. *Mol Aspects of Medicine* 22, 247-284 (2001).
- Szebenyi G, Fallon JF. Fibroblast growth factors as multifunctional signaling factors. *Int Rev Cytol* 185: 45-106 (1999).

Tordjman K, Standley KN, Bernal-Mizrachi C, Leone TC, Coleman T, Kelly DP, Semenkovich CF. PPAR α suppresses insulin secretion and induces UCP2 in insulinoma cells. *J Lipid Res.* 43:936-943 (2002).

Zhou YP, Marlen K, Palma JF, Schweitzer A, Reilly L, Gregoire FM, Xu GG,

- 5 Blume JE, Johnson JD. Overexpression of repressive cAMP response element modulators in high glucose and fatty acid-treated rat islets. A common mechanism for glucose toxicity and lipotoxicity? *J Biol Chem.* 278:51316-51323 (2003).

- 10 Zraika, S, Dunlop, M, Proietto, J, Anrikopoulos. Effects of free fatty acids on insulin secretion in obesity. *Obesity reviews*, 3:103-112, 2002.

Yonezawa T, Katoh K, Obara Y Existence of GPR40 functioning in a human breast cancer cell line, MCF-7. *Biochem Biophys Res Commun.* 314:805-809 (2004).

- 15 Hull RL, Westermark GT, Westermark P, Kahn SE. Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes. *J Clin Endocrinol Metab.* 2004 Aug;89(8):3629-43.

β -Cell-specific inactivation of the mouse *Ipf1/Pdx1* gene results in loss of the β -cell phenotype and maturity onset diabetes.

Ulf Ahlgren, Jörgen Jonsson, Lena Jonsson, Karin Simu, and Helena Edlund.

- 20 *Genes and Development* 1998 12: 1763-1768.

Type 2 Diabetes: An overview. Harold Lebovitz
Clinical Chemistry 1999 45:8(B), 1339-1345.

Knut Kotarsky, Niclas E. Nilsson, Erik Flodgren, Christer Owman, and Björn Olde. *Biochemical and Biophysical Research Communications* 301 (2003)
25 406-410.

Lipotoxicity: When tissues overeat. Jean E. Schaffer. *Curr Opin Lipidol* 2003 14:281-287.

Claims

1. A transgenic laboratory animal over-expressing GPR40 comprising the promotor *lpl1/Pdx1* for controlling the expression of GPR40.

5

2. The transgenic animal of claim 1, wherein the animal is a rodent.

3. The transgenic animal of claim 2, wherein the animal is a mouse or a rat.

10 4. A method for testing whether a chemical compound possessing a certain effect for treating diabetes Type 2 using a transgenic laboratory animal comprising the steps of:

a) providing a chemical compound to be tested;

b) providing a transgenic laboratory animal according to claim 1;

15 c) exposing said animal to said chemical compound; and

d) determining whether said chemical compound has an effect on the blood glucose level in said animal.

20 5. A method for testing whether a chemical compound possessing a certain effect for treating diabetes Type 2 using a transgenic laboratory animal comprising the steps of:

a) providing a chemical compound to be tested;

b) providing a transgenic laboratory animal according to claim 1;

c) exposing said animal to said chemical compound; and

25 d) determining whether said chemical compound has an effect on the triglyceride level in said animal.

30 6. A method for testing whether a chemical compound possessing a certain effect for treating diabetes Type 2 using a transgenic laboratory animal comprising the steps of:

a) providing a chemical compound to be tested;

- b) providing a transgenic laboratory animal according to claim 1;
- c) exposing said animal to said chemical compound; and
- d) determining whether said chemical compound has an effect on the low density lipoprotein (LDL) level in said animal.

5

7. A method for testing whether a chemical compound possessing a certain effect for treating diabetes Type 2 using a transgenic laboratory animal comprising the steps of:

- a) providing a chemical compound to be tested;
- 10 b) providing a transgenic laboratory animal according to claim 1;
- c) exposing said animal to said chemical compound; and
- d) determining whether said chemical compound has an effect on the high density lipoprotein (HDL) level in said animal.

- 15 8. A method for testing whether a chemical compound possessing a certain effect for treating diabetes Type 2 using a transgenic laboratory animal comprising the steps of:

- a) providing a chemical compound to be tested;
- b) providing a transgenic laboratory animal according to claim 1;
- 20 c) exposing said animal to said chemical compound; and
- d) determining whether said chemical compound has an effect on the free fatty acids in said animal.

- 25 9. A method for testing whether a chemical compound possessing a certain effect for treating diabetes Type 2 using a transgenic laboratory animal comprising the steps of:

- a) providing a chemical compound to be tested;
- b) providing a transgenic laboratory animal according to claim 1;
- c) exposing said animal to said chemical compound; and
- 30 d) determining whether said chemical compound has an effect on the glucose tolerance content in said animal.

Figure 1




Figure 2a




Figure 2b




Figure 3a




Figure 3b




Figure 4a




Figure 4b




Figure 5a-h




Figure 6a




Figure 6b




Figure 7a




Figure 7b




Figure 8a




Figure 8b





Figure 9



1Kb

E=EcoRI

X=XhoI

K=KpnI

B=BamHI

SEQUENCE LISTING

<110> Betagenon AB
Yeda Research and Development Company Limited

<120> NEW ANIMAL MODEL

<130> 72739-76931

<150> US 60/481,249

<151> 2003-08-18

<150> US 60/481,608

<151> 2003-11-07

<150> US 60/521,377

<151> 2004-06-22

<160> 4

<170> PatentIn version 3.2

<210> 1

<211> 300

<212> PRT

<213> Mus musculus

<400> 1

Met Asp Leu Pro Pro Gln Phe Ser Phe Ala Leu Tyr Val Ser Ala Phe
1 5 10 15

Ala Leu Gly Phe Pro Leu Asn Leu Leu Ala Ile Arg Gly Ala Val Ser
20 25 30

His Ala Lys Leu Arg Leu Thr Pro Ser Leu Val Tyr Thr Leu His Leu
35 40 45

Gly Cys Ser Asp Leu Leu Leu Ala Ile Thr Leu Pro Leu Lys Ala Val
50 55 60

Glu Ala Leu Ala Ser Gly Ala Trp Pro Leu Pro Leu Pro Phe Cys Pro
65 70 75 80

Val Phe Ala Leu Ala His Phe Ala Pro Leu Tyr Ala Gly Gly Gly Phe
85 90 95

Leu Ala Ala Leu Ser Ala Gly Arg Tyr Leu Gly Ala Ala Phe Pro Phe
100 105 110

Gly Tyr Gln Ala Ile Arg Arg Pro Arg Tyr Ser Trp Gly Val Cys Val
115 120 125

Ala Ile Trp Ala Leu Val Leu Cys His Leu Gly Leu Ala Leu Gly Leu
130 135 140

Glu Thr Ser Gly Ser Trp Leu Asp Asn Ser Thr Ser Ser Leu Gly Ile
145 150 155 160

Asn Ile Pro Val Asn Gly Ser Pro Val Cys Leu Glu Ala Trp Asp Pro
165 170 175

Asp Ser Ala Arg Pro Ala Arg Leu Ser Phe Ser Ile Leu Leu Phe Phe
 180 185 190
 Leu Pro Leu Val Ile Thr Ala Phe Cys Tyr Val Gly Cys Leu Arg Ala
 195 200 205
 Leu Val Arg Ser Gly Leu Ser His Lys Arg Lys Leu Arg Ala Ala Trp
 210 215 220
 Val Ala Gly Gly Ala Leu Leu Thr Leu Leu Leu Cys Leu Gly Pro Tyr
 225 230 235 240
 Asn Ala Ser Asn Val Ala Ser Phe Ile Asn Pro Asp Leu Gly Gly Ser
 245 250 255
 Trp Arg Lys Leu Gly Leu Ile Thr Gly Ala Trp Ser Val Val Leu Asn
 260 265 270
 Pro Leu Val Thr Gly Tyr Leu Gly Thr Gly Pro Gly Arg Gly Thr Ile
 275 280 285
 Cys Val Thr Arg Thr Gln Arg Gly Thr Ile Gln Lys
 290 295 300

<210> 2
 <211> 903
 <212> DNA
 <213> Mus musculus

<220>
 <221> misc_feature
 <222> (67)..(393)
 <223> transmembrane receptor

<400> 2
 atggacctgc cccacagtt ctccttcgct ctctatgtat ctgcctttgc gctgggcttt
 60
 ccattgaact tgtagccat ccgaggcgca gtgtcccacg ctaaactgcg actcactccc
 120
 agcttggtct acactctcca tctgggctgc tctgatctcc tactggccat cactctgccc
 180
 ctgaaggctg tggaggccct ggcttctgga gcctggcccc tgccgctccc cttctgccc
 240
 gtctttgcct tggcccaatt tgcctccctc tacgcaggcg gaggcttcct agctgctctc
 300
 agcgtggcc gctacctggg ggctgccttc cccttcgggt accaagccat ccggaggccc
 360
 cgctattcct ggggtgtgtg tgtggctata tgggcccctg tcctctgcca cctggggctg
 420
 gcccttggct tggagacttc cggaagctgg ctggacaaca gtaccagttc cctgggcatc
 480

aacatacccg tgaatggctc cccggtctgc ctggaagcct gggatcccga ctctgcccg
540

cctgcccgtc tcagtttctc cattctgctc ttctttctgc cettgggtcat cactgccttc
600

tgctatgtgg gctgcctccg ggcctgggtg cgctcaggcc tgagccacaa acggaagctc
660

agggcagctt ggggtggccgg aggcgctctc ctcaactcc tgctctgcct ggggccctat
720

aatgcctcca atgtggctag tttcataaac ccggacctag gaggctcctg gaggaagtgtg
780

ggactcatca caggggcctg gagtgtggta ctcaaccac tggtcactgg ctacttggga
840

acaggtcctg gacggggaac aatatgtgtg acgaggactc aaagaggaac aattcagaag
900

tag
903

<210> 3
<211> 21
<212> DNA
<213> Unknown

<220>
<223> primer

<400> 3
gggaagagga gatgtagact t
21

<210> 4
<211> 18
<212> DNA
<213> Unknown

<220>
<223> primer

<400> 4
gtagagggga gcaaagtg
18

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 2004/001209

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: A01K 67/027

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: A01K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPI, EPO-INTERNAL, PAJ, BIOSIS, EMBASE, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 0176361 A1 (ELINUS AB), 18 October 2001 (18.10.2001), abstract, page 1, lines 5-14; page 4, lines 6-14; examples 1-6 --	1-9
Y	WO 02057783 A2 (GLAXO GROUP LIMITED), 25 July 2002 (25.07.2002), page 4, line 7 - line 16; page 6, line 15 - line 16; page 7, line 1 - line 13, page 8, line 9 - line 12; page 17, line 29 - page 18, line 12; page 20, line 4 - line 6; examples 2-4, claims 24 and 27-28 --	1-9
Y	Nature, Volume 422, March 13, 2003, Yasuaki Itoh et al, "Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40", page 6928, abstract --	1-9

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"I" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

17 January 2005

Date of mailing of the international search report

19-01-2005

Name and mailing address of the ISA/

Swedish Patent Office

Box 5055, S-102 42 STOCKHOLM

Facsimile No. +46 8 666 02 86

Authorized officer

TERESE PERSSON/BS

Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 2004/001209

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	The Journal of Biological Chemistry, Volume 278, No. 13, March 2003, Celia P. Briscoe et al, "The Orphan G Protein-coupled Receptor GPR40 Is Activated by Medium and Long Chain Fatty Acids", pages 11303-11311 --	1-9
P,X	DATABASE WPI Week 200363 Derwent Publication Ltd., London, GB; Class B04, AN 2003-671661 & W003068959 A1 (TAKEDA CHEM IND LTD), 21 Augusti 2003 (2003-08-21) abstract -- -----	1-9

INTERNATIONAL SEARCH REPORTInternational application No.
PCT/SE2004/001209**Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.b of the first sheet)**

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, the international search was carried out on the basis of:

a. type of material

- ☒ a sequence listing
☐ table(s) related to the sequence listing

b. format of material

- ☒ in written format
☒ in computer readable form

c. time of filing/furnishing

- ☒ contained in the international application as filed
☒ filed together with the international application in computer readable form
☐ furnished subsequently to this Authority for the purposes of search

2. ☐ In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.

3. Additional comments:

INTERNATIONAL SEARCH REPORT

Information on patent family members

30/10/2004

International application No.

PCT/SE 2004/001209

WO	0176361	A1	18/10/2001	AT	247634	T	15/09/2003
				AU	4702201	A	23/10/2001
				AU	6033400	A	31/01/2001
				CA	2414652	A	18/10/2001
				DE	60004675	D,T	17/06/2004
				EP	1196376	A,B	17/04/2002
				SE	1196376	T3	
				EP	1292186	A	19/03/2003
				IL	152135	D	00/00/0000
				JP	2003503382	T	28/01/2003
				JP	2003529379	T	07/10/2003
				SE	0001285	D	00/00/0000
				US	6770679	B	03/08/2004
				US	20030056240	A	20/03/2003
				ZA	200208694	A	19/08/2003

WO	02057783	A2	25/07/2002	EP	1354200	A	22/10/2003
				GB	0031527	D	00/00/0000
				US	20040137517	A	15/07/2004
